Mavligit G M, Gutterman J U, Hersh E M
J Natl Cancer Inst. 1976 Oct;57(4):749-51. doi: 10.1093/jnci/57.4.749.
Studies of primary sensitization and delayed hypersensitivity reactions to 2,4-dintrochlorobenzene (DNCB) and recall antigens were conducted in 71 patients with melanoma who were receiving BCG (Tice strain) immunotherapy by scarification. Similar studies were conducted in 32 control patients with melanoma who did not receive BCG. No significant differences were observed, in the various clinical stages, between patients receiving and those not receiving BCG, in terms of the frequency or intensity of primary sensitization to DNCB. Furthermore, there was no significant difference in delayed hypersensitivity to recall antigens between these groups of patients. The apparent discrepancy between the clinical benefit from BCG immunotherapy and its failure to stimulate certain parameters of cellular immunity in patients with melanoma is discussed.
对71例接受划痕法接种卡介苗（Tice株）免疫治疗的黑色素瘤患者进行了对2,4 - 二硝基氯苯（DNCB）的初次致敏和迟发型超敏反应以及回忆抗原的研究。对32例未接受卡介苗的黑色素瘤对照患者进行了类似研究。在各个临床阶段，接受和未接受卡介苗的患者之间，就对DNCB的初次致敏频率或强度而言，未观察到显著差异。此外，这些患者组之间在对回忆抗原的迟发型超敏反应方面也没有显著差异。讨论了卡介苗免疫治疗在临床上的益处与其未能刺激黑色素瘤患者某些细胞免疫参数之间明显的差异。
